WESTLAKE VILLAGE, Calif., July 07, 2025 ( GLOBE NEWSWIRE ) -- Genelux Corporation GNLX, a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July ...

WESTLAKE VILLAGE, Calif., July 07, 2025 ( GLOBE NEWSWIRE ) -- Genelux Corporation ( NASDAQ: GNLX ) , a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, ...

Genelux Corporation (GNLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here is how EUROFINS SCIENT (ERFSF) and Genelux Corporation (GNLX) have performed compared to their sector so far this year.

Genelux Corporation (GNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

WESTLAKE VILLAGE, Calif., March 25, 2025 ( GLOBE NEWSWIRE ) -- Genelux Corporation ( "Genelux" ) ( Nasdaq: GNLX ) , a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 3,000,000 shares of its common stock at an offering price of $3.50 per ...

WESTLAKE VILLAGE, Calif., Feb. 03, 2025 ( GLOBE NEWSWIRE ) -- Genelux Corporation GNLX, a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025.